Ionis is set to launch olezarsen, its first fully owned drug, following promising Phase 3 trial outcomes.

Recent data presented at the American College of Cardiology revealed olezarsen's significant impact, reducing triglyceride levels by 44% compared to placebo.

The trial's strong p-value of less than 0.001 suggests the results are statistically significant.

Olezarsen has shown potential efficacy in treating familial chylomicronemia syndrome, a rare genetic disorder.

Ionis is moving forward with a New Drug Application for olezarsen, bolstered by the supportive trial data.